Phase 3 N=1,062 Adaptive COVID-19 Treatment Trial (ACTT)
COVID-19
Primary: Time to Recovery — 15; 10 Days — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=203 TeleHepC Treatment Trial
Hepatitis C
Primary: Viral Response — 63; 16 Participants
N/A N=9,159 To Estimate the Efficacy of Treatment With TNFi as Monotherapy or Combination Therapy With MTX and Compare and Contrast Efficacy With Tofacitinib as Monotherapy and Combination Therapy in a Real World Setting.
Rheumatoid Arthritis
Primary: Clinical Disease Activity Index (CDAI) Score at 6 Months for Tofacitinib Monotherapy vs Tofacitinib With Methotrexate (MTX) — 18.1; 17; 16.6; 14.6 Units on a scale
Phase 4 N=700 Sequenced Treatment Effectiveness for Posttraumatic Stress
PTSD
Primary: PTSD Symptoms — 39.3; 38.6; 40.5 units on a scale
N/A N=156 Comparison of Telemedicine to Usual Care for HCV Management for Methadone-maintained Individuals
Hepatitis C
Primary: Observed Percentage of Patients in Both Arms Who Achieve Viral Eradication — 106; 246 Participants
Phase 3 N=426 A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment
Human Immunodeficiency Virus-type 1 Infection
Primary: Percentage of Participants With Plasma Human Immunodeficiency Virus - Type 1 Ribonucleic Acid (HIV-1 RNA) Levels Less Than (<) 400 Copies Per Milliliter (Copies/mL) at…
Phase 2 N=84 The Effects of Adding TCM-700C on the Standard Combination Treatment for Patients With Genotype 1 Hepatitis C Infection
Chronic Hepatitis C
Primary: Sustained Virologic Response (SVR) — 27; 29 Number of participants with SVR
N/A N=327 Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Number of Patients in Symptomatic Remission at Week 8 Comparing the "Switched" With the "Non Switched" Early Non-responders — 41; 25 Participants — p==0.01
N/A N=62 Efficacy, Safety of T2769 in Dry Eye Disease
Dry Eye Syndrome
Primary: Ocular Symptomatology — -55.9 units on a scale
Phase 3 N=244 Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease
Crohn's Disease
Primary: Percentage of Participants With Mucosal Healing and No Deep Ulcerations — 30.3; 45.9 percentage of participants — p=0.010
N/A N=59 Trial to Assess the Impact of PrEP to Tenofovir Gel on the Efficacy of Tenofovir-containing ART on Viral Suppression
Antiretroviral Treatment Outcomes
Primary: The Antiretroviral Treatment Failure Rate at 12 Months. — 4; 5 participants — p=1.00
N/A N=10 Development of a Community-based HCV Treatment Completion Intervention Among HCV Positive Homeless Adults
Hepatitis C Virus (HCV) Infection
Primary: Number of Participants Completing HCV Treatment — 3; 6 Participants
Phase 2 N=35 The Effectiveness and Efficacy of the Combination of the Integrated Psychological Therapy and Metacognitive Training.
Schizophrenia
Primary: Cognitive Functions: Matrics Consensus Cognitive Battery (MCCB), Greek Verbal Test — 12.09; 19.04; 7.71; 14.00 score on a scale — p=.00
Phase 3 N=55 Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
HIV · HIV Infections · Acquired Immunodeficiency Syndrome
Primary: Part 1: Percentage of Participants With Plasma HIV-1 RNA Decreases From Baseline Exceeding 0.5 log10 at Day 10 — 58.3; 60.7; 0 percentage of participants — p=<0.001
Phase 3 N=31 Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB
Dystrophic Epidermolysis Bullosa · Recessive Dystrophic Epidermolysis Bullosa · Dominant Dystrophic Epidermolysis Bullosa
Primary: Primary Wound With Complete Wound Healing (100% Wound Closure) on Weeks 22 and 24 or Weeks 24 and 26 — 20.9; 6.7 number of wounds with complete healing — p=0.00192
Phase 3 N=678 TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
HIV Infections · HIV-1
Primary: Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies Per mL) at Week 48 — 291; 276; 24; 18…
Phase 3 N=690 TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.
HIV Infections · HIV-1 · Human Immunodeficiency Virus Type 1
Primary: Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies/ml) at Week 48 — 287; 285; 38; 15 Participants…
Phase 3 N=109 A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care
HIV-1
Primary: Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Less Than (<) 50 Copies Per Milliliter (Copies/mL) (Virologic Response) at…
N/A N=1 Actigraphic Analysis of Treatment Response
Sleep Disorders, Circadian Rhythm · Insomnia · Psychomotor Agitation
Primary: Actigraphic Measurement of Treatment Conditions — 55.02; 9.94 activity
Phase 1 N=42 Phase I Combination w/ Epirubicin
Metastatic Breast Cancer
Primary: Number of Participants With a Dose Limiting Toxicity (DLT) — 1; 1; 2; 1 Participants
Phase 3 N=630 Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)
HIV Infections
Primary: Treatment Response at Week 48 — 33.80; 16.20 percentage of participants — p=0.0001
Phase 4 N=270 Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)
Hepatitis B, Chronic
Primary: Number of Participants With HBV DNA <20 IU Per mL — 257; 261; 257; 256 Participants
Phase 2 N=50 A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
Melanoma
Primary: Objective Tumor Response Rate — 28 percentage of participants
Phase 3 N=114 Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up
Opioid-use Disorder · Hiv
Primary: Number of Participants With HIV Viral Suppression, Missing Imputed as Unsuppressed — 23; 21; 29; 29 Participants
Phase 3 N=274 Testosterone Treatment for Hypogonadal Men
Hypogonadism
Primary: Percentage of Subjects on Testosterone Treatment Achieving Target Range for Testosterone Cav (Time-averaged Concentration Over the Dosing Interval of 24 Hours) on Day…
N/A N=3,172 Study Evaluating The Safety And Effectiveness In Subjects With Tigecycline Treatment
Complicated Skin and Skin Structure Infections · Complicated Intra-abdominal Infections · Community-Acquired Bacterial Pneumonia
Primary: Percentage of Participants With Adverse Events (AEs)/Adverse Drug Reactions (ADRs), Serious AEs (SAEs)/Serious ADRs (SADRs), and Unexpected AEs/ADRs — 32.98; 9.85…
Phase 3 N=701 Optimization of the TB Treatment Regimen Cascade
Tuberculosis, Pulmonary
Primary: Tuberculose Treatment Outcome — 8; 8; 11; 5 Participants
N/A N=399 Effectiveness of Transdiagnostic Cognitive Behavioral Therapy for Improving HIV Treatment Outcomes in South Africa
HIV/AIDS · Violence
Primary: 12 Month Viral Suppression — 86; 86 Participants
Phase 3 N=549 Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa
Acute Otitis Externa
Primary: Proportion of Patients With Clinical Cures at the Day 11 (TOC) Visit — 68.7; 40.0 Percentage of participants
N/A N=568 Older Adult Effectiveness of 2 Treatments
Dental Caries
Primary: Caries Arrest Rate — 0.75; 0.91 surfaces